 |
Long-term treatment is essential to ensure effective management of functional constipation, as early discontinuation, may lead to relapse.1 |
 |
Indian Academy of Pediatrics recommends that the child should be symptom-free while on maintenance therapy for at least 6 months before attempting to taper the laxatives.2 |
 |
PEG offers a safe and effective choice for long-term treatment.1,2 |
 |
A prospective observational study evaluated the safety profile of PEG therapy in 83 children with functional constipation, who received treatment for a period of 3 to 30 months.1 |
 |
With dose reduction, the most common adverse events of loose or frequent stools improved.1 |
 |
Despite improvement in stool frequency and consistency, long-term PEG therapy did not have any adverse effects on renal function, electrolyte levels, serum albumin levels, and osmolality.1 |
 |
No treatment discontinuation was reported due to adverse events.1 |
Abbreviations ▼
PEG: Polyethylene glycol.
References ▼
1. Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med. 2003;157(7):661–664. 2. Yachha SK, Srivastava A, Mohan N, et al. Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition Committee on Childhood Functional Constipation; Pediatric Gastroenterology Subspecialty Chapter of Indian Academy of Functional Constipation; and Pediatric Gastroenterology Subspecialty Chapter of Indian Academy of Pediatrics. Management of childhood functional constipation: Consensus Practice Guidelines of Indian Society of Pediatric Gastroenterology. Indian Pediatr. 2018;55(10):885–892.
LMRC Code: GGI-CO-A1-AQS-300024228-ELC-I24-1577
For the use of a Registered Medical Practitioner, Hospital or Laboratory only.
Disclaimer:
The images are for illustrative representation only and do not depict actual medical products, procedures, or outcomes. Refer to official medical guidance and product information for accurate details.
All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy’s Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy’s.
